The stem cell therapy for osteoarthritis pipeline analysis report includes ongoing clinical and non-clinical trends in the global stem cell therapy for osteoarthritis. Majority of the pipeline therapeutics are in early stages of development. There is no cure for the disease, but treatments are available to manage the symptoms. A long-lasting and less-frequent dose can impact overall osteoarthritis market.
The global osteoarthritis market is expected to grow at a CAGR of 8.55% over the period of 2014-2019. The expected growth is because of increasing awareness of osteoarthritis and increasing diagnosis rates, rising older population, and increasing cases of obesity. Osteoarthritis is directly related to obesity, with approximately 37% of osteoarthritis patients suffering from obesity.
Covered in this report
The report covers the present scenario and the growth prospects of the stem cell therapy for osteoarthritis. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
Technavio's Stem Cell Therapy for Osteoarthritis - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.
- U.S. Stem Cell
- Asterias Biotherapeutics
- How will the market evolve during the forecast period?
- What are the major parameters impacting the market?
- What are the key market trends?
- What are the challenges to market growth?
- Who are the key companies in this market space?
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: STEM CELL THERAPY FOR OSTEOARTHRITIS: AN INSIGHT
PART 07: COMPARATIVE ANALYSIS
- Late-stage molecule (Phase III)
- Mid-stage molecules (Phase II and Phase I/II)
- Early-stage molecules (Phase I and pre-clinical)
- Inactive molecules
PART 09: THERAPEUTIC ASSESSMENT BY THERAPY
- Therapeutic assessment based on therapy
- Therapeutic assessment based on RoA
- Therapeutic assessment based on RoA in various stages of development
- Active companies: Category and parameters
- List of abbreviations
Exhibit 01: Drug approval process by US FDA
Exhibit 02: Pipeline molecules by vendors
Exhibit 03: Pipeline landscape
Exhibit 04: Pipeline molecules in different developmental stages 2017
Exhibit 05: Percentage of pipeline molecules in different developmental stages 2017
Exhibit 06: Overview: GID SVF
Exhibit 07: Clinical trials description of autologous adipose-derived SVF cells
Exhibit 08: Overview: ReJoin
Exhibit 09: Clinical trials description of ReJoin (mesenchymal progenitor cells)
Exhibit 10: Overview: Autologous regenerative cell therapy
Exhibit 11: Clinical trials description of autologous regenerative cell therapy
Exhibit 12: Overview: MSB-CAR001
Exhibit 13: Clinical trials description of MSB-CAR001
Exhibit 14: Overview: Stempeucel
Exhibit 15: Clinical trials description of Stempeucel osteoarthritis
Exhibit 16: Overview: Stemchymal
Exhibit 17: Clinical trials description of Stemchymal
Exhibit 18: Overview: Elixcyte
Exhibit 19: Clinical trials description of Elixcyte
Exhibit 20: Overview: AlloJoin
Exhibit 21: Clinical trials description of AlloJoin
Exhibit 22: Overview: Human Umbilical Cord MSCs
Exhibit 23: Clinical trials description of Human umbilical cord MSCs
Exhibit 24: Overview: Progenza
Exhibit 25: Clinical trials description of Progenza
Exhibit 26: Overview: Adipose-derived stromal cells
Exhibit 27: Clinical trials description of Adipose-derived stromal cells
Exhibit 28: Overview: ALLO-ASC-OA
Exhibit 29: Overview: GRNCHND1
Exhibit 30: Overview: Stem cell therapy for osteoarthritis
Exhibit 31: Overview: Allogeneic mesenchymal stem cell candidate
Exhibit 32: Inactive molecules 2017
Exhibit 33: Analysis by indication
Exhibit 34: Assessment of stem cell therapy for osteoarthritis by therapy
Exhibit 35: Assessment of stem cell therapy for osteoarthritis by RoA
Exhibit 36: Assessment of stem cell therapy for osteoarthritis by stage and RoA
Exhibit 37: Active companies: Category and parameters 2017
Exhibit 38: Segmentation of companies 2017
Exhibit 39: Overview: Anterogen 2017
Exhibit 40: Overview: Asterias Biotherapeutics 2017
Exhibit 41: Overview: Cellular Biomedicine Group 2017
Exhibit 42: Overview: Mesoblast 2017
Exhibit 43: Overview: Regeneus 2017
Exhibit 44: Overview: OrthoCyte* 2017
Exhibit 45: Overview: Shenzhen Hornetcorn Bio-technology 2017
Exhibit 46: Overview: Steminent Biotherapeutics 2017
Exhibit 47: Overview: Stempeutics Research 2017
Exhibit 48: Overview: The GID Group 2017
Exhibit 49: Overview: UnicoCell Biomed 2017
Exhibit 50: Overview: U.S. Stem Cell 2017
Exhibit 51: Overview: VivaTech International 2017
Exhibit 52: Overview: Xintela 2017
The author of the report recognizes the following companies in the stem cell therapy for osteoarthritis: Mesoblast, Regeneus, U.S. Stem Cell, Anterogen, Asterias Biotherapeutics.
The "Stem cell therapy for osteoarthritis - A pipeline analysis report, 2017” provides comprehensive insights about pipeline molecules across this approach of treatment. The key objective of the report is to establish the understanding of all the pipeline molecules that fall under osteoarthritis stem cell therapy.
This report provides information on the therapeutic development based on the stem cell therapy for osteoarthritis dealing with all the pipeline drugs; comparative analysis at various stages covering Phase III, Phase II, Phase I/II, and pre-clinical; therapeutics assessment by monotherapy and combination products; and molecule type drug information. The report also covers the information of companies that are involved in the development of pipeline products. It also highlights the dormant products.
Degenerative joint disease and “wear and tear” arthritis are some of the synonyms used for osteoarthritis. It is the most common chronic condition of the joints, which features the breakdown and eventual loss of the cartilage of one or more joints. Osteoarthritis occurs mostly in knees; however, it can affect any joints such as hips, lower back, neck, small joints of the fingers, and the bases of the thumb and big toe. Osteoarthritis can occur in people of all ages and sex, but it is most common in people older than 65 years. The basic difference between rheumatoid arthritis and osteoarthritis is that the rheumatoid arthritis is an autoimmune disease characterized by an overactive, misdirected immune system while osteoarthritis is a disease of the cartilage of joints, and it is not a systemic disease or an autoimmune disease.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.